
Roberto Bortolus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3002509/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1387-1398.	6.4	304
2	Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. New England Journal of Medicine, 2003, 348, 2396-2406.	27.0	301
3	Hepatitis C virus and nonâ€Hodgkin's lymphomas. British Journal of Haematology, 1996, 94, 544-550.	2.5	171
4	Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 19-30.	0.8	71
5	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	2.2	69
6	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncology, 2014, 10, 975-983.	2.4	43
7	What elderly cancer patients want to know? Differences among elderly and young patients. Psycho-Oncology, 2007, 16, 365-370.	2.3	41
8	Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. Journal of Neuro-Oncology, 2012, 107, 191-196.	2.9	40
9	Management of metastatic castration-resistant prostate cancer: A focus on radium-223. Critical Reviews in Oncology/Hematology, 2017, 113, 43-51.	4.4	28
10	Pros-IT CNR: an Italian prostate cancer monitoring project. Aging Clinical and Experimental Research, 2017, 29, 165-172.	2.9	26
11	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health and Quality of Life Outcomes, 2018, 16, 122.	2.4	24
12	Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre crossâ€sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. BJU International, 2016, 117, 867-873.	2.5	23
13	Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC) Tj ETQ	q110.784	4314 rgBT /0 22
14	Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. Urology, 2016, 96, 165-170.	1.0	21
15	Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. Cancer, 1994, 74, 978-984.	4.1	20
16	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) Tj ETQq0 0 0 rgl	BT1/Øverlo	ch200 Tf 50 1
17	Radiation Therapy Combined with Chemotherapy for Inoperable Pancreatic Carcinoma. Tumori, 1991, 77, 61-64.	1.1	18

18	Multiple fraction per day radiation therapy for inoperable esophageal cancer. International Journal of Radiation Oncology Biology Physics, 1988, 14, 855-860.	0.8	17
	of Radiation Oncology Biology Physics, 1988, 14, 855-860.		

ROBERTO BORTOLUS

#	Article	IF	CITATIONS
19	Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study. Radiotherapy and Oncology, 1992, 23, 241-244.	0.6	17
20	Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial. Radiation Oncology, 2014, 9, 24.	2.7	17
21	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumor Biology, 2016, 37, 9855-9863.	1.8	15
22	²²³ Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori, 2018, 104, 128-136.	1.1	14
23	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) Tj ETQq1 1 0.784314 2021, 38, 527-537.	rgBT /Ove	erlock 10 Tf 5
24	Accelerated split course regimen in the treatment of brain metastases. Radiotherapy and Oncology, 1988, 12, 39-44.	0.6	12
25	Feasibility of Total Body Irradiation in Chronic Lymphocytic Leukemia and Low-Grade Non-Hodgkin's Lymphomas. Cancer Investigation, 1991, 9, 403-407.	1.3	9
26	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. Oncotarget, 2017, 8, 22863-22875.	1.8	9
27	Results of Three Consecutive Combined Treatments for Malignant Gliomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 437-443.	1.3	8
28	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology, 2016, 12, 493-502.	2.4	8
29	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS ONE, 2019, 14, e0224151.	2.5	8
30	Postoperative Radiotherapy in Locally Advanced Head and Neck Cancer. Tumori, 1989, 75, 47-52.	1.1	7
31	Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer. Gynecologic Oncology, 1991, 41, 206-211.	1.4	7
32	Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 508-515.	3.9	7
33	rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. International Journal of Molecular Sciences, 2019, 20, 2082.	4.1	6
34	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	2.5	6
35	Solitary Thyroid Metastasis from a Renal Cell Carcinoma Diagnosed and Treated 12 Years before: A Case Report. Tumori, 1995, 81, 450-453.	1.1	3
36	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study) Journal of Clinical Oncology, 2014, 32, 92-92.	1.6	2

#	Article	IF	CITATIONS
37	Hyperthermia in Clinical Practice: Preliminary Results and Current Problems in the Treatment of 21 Patients. Tumori, 1992, 78, 262-265.	1.1	1
38	499 oral SALVAGE OR ADJUVANT? 5Y-RESULTS OF THE "AIRO NATIONAL WORKING GROUP ON PROSTATE RADIOTHERAPY―MULTICENTER PROSPECTIVE STUDY. Radiotherapy and Oncology, 2011, 99, S202.	0.6	1
39	Weekly cabazitaxel in elderly patients (EP) with metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel treatment: WeCabE, a phase II study Journal of Clinical Oncology, 2018, 36, 300-300.	1.6	1
40	Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers Journal of Clinical Oncology, 2018, 36, 322-322.	1.6	1
41	7059 POSTER Incidence and Outcomes of Brain and Meningeal Metastases (BMm) in Patients With Castration-resistant Prostate Cancer (CRPC) in the Era of Docetaxel (DOC). European Journal of Cancer, 2011, 47, S503.	2.8	0
42	220 ADJUVANT OR SALVAGE RADIOTHERAPY? FIVE YEAR RESULTS OF THE "AIRO NATIONAL WORKING GROUP ON PROSTATE RADIOTHERAPY―MULTICENTER PROSPECTIVE STUDY. European Urology Supplements, 2011, 10, 91.	р 0.1	0
43	The German Hodgkin Study Group Stratification Scheme for Newly Diagnosed Hodgkin Lymphoma Is Useful for Predicting Outcome of Patients Receiving Radiation Therapy After Autologous Self Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics. 2014. 90. S671.	0.8	0
44	Towards the multidisciplinary management of prostate cancer patients: the PerSTEP Project experience. Annals of Oncology, 2015, 26, vi57.	1.2	0
45	MP53-14 MULTIMODAL TREATMENT FOR HIGH-RISK PROSTATE CANCER WITH HIGH-DOSE INTENSITY-MODULATED RADIATION THERAPY, CONCURRENT INTENSIFIED-DOSE DOCETAXEL AND LONG-TERM ANDROGEN DEPRIVATION THERAPY AFTER RADICAL PROSTATECTOMY AND LYMPHADENECTOMY: RESULTS OF A PROSPECTIVE PHASE II TRIAL., Journal of Urology, 2017, 197.	0.4	0
46	A phase II noncomparative study of neoadjuvant (NA) chemohormone therapy (CHT), radical prostatectomy (RP), and postoperative radiotherapy (RT) in locally advanced (LA) high-risk prostate cancer (HRPC): A monoinstitutional 6-year experience with two NA CHT regimens. Journal of Clinical Oncology, 2009, 27, e16091-e16091.	1.6	0
47	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP) Journal of Clinical Oncology, 2013, 31, 189-189.	1.6	0